RecruitingPhase 2NCT06742424

PD-L1 Antibody + Bevacizumab With Hepatic Arterial Infusion Chemotherapy for Advanced HCC

Studying Combined hepatocellular carcinoma and cholangiocarcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
West China Hospital
Intervention
PD-L1 antibody(drug)
Enrollment
36 target
Eligibility
18-75 years · All sexes
Timeline
20242027

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06742424 on ClinicalTrials.gov

Other trials for Combined hepatocellular carcinoma and cholangiocarcinoma

Additional recruiting or active studies for the same condition.

See all trials for Combined hepatocellular carcinoma and cholangiocarcinoma

← Back to all trials